Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Buy" from Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus rating of "Buy" from the ten research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $64.67.

VERA has been the subject of a number of research analyst reports. Wolfe Research began coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price on the stock. Guggenheim upped their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. cut their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Huntington National Bank bought a new stake in shares of Vera Therapeutics in the 4th quarter valued at $26,000. AlphaQuest LLC acquired a new stake in Vera Therapeutics during the 4th quarter worth about $34,000. GF Fund Management CO. LTD. bought a new position in shares of Vera Therapeutics in the 4th quarter worth about $56,000. KBC Group NV raised its position in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its position in shares of Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

VERA opened at $23.37 on Thursday. The firm has a market cap of $1.49 billion, a P/E ratio of -8.95 and a beta of 1.28. The business's fifty day moving average is $24.93 and its 200-day moving average is $35.56. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. Sell-side analysts expect that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.